Table 1 General and laboratory characteristics and drug history of the study population according to PLR quartiles
Variables | Total | PLR quartiles | P | |||
|---|---|---|---|---|---|---|
(n = 405) | Q1 (PLR ≤ 118) (n = 100) | Q2 (119 < PLR < 198) (n = 103) | Q3 (198 ≤ PLR < 268) (n = 101) | Q4 (PLR ≥ 268) (n = 101) | ||
Age(years) | 65.9 ± 13.49 | 65.3 ± 13.15 | 66.5 ± 12.8 | 65.7 ± 12.91 | 66.25 ± 15.13 | 0.913 |
Males (%) | 274 (67.7) | 72 (72) | 68 (66) | 64 (63.4) | 70 (69.3) | 0.580 |
BMI(kg/m2) | 26.85 ± 6.2 | 26.45 ± 6.9 | 27.49 ± 7.2 | 27.32 ± 6 | 26.32 ± 3.9 | 0.417 |
Heart rate (beats per minute) | 85.28 ± 19.5 | 83.64 ± 20.3 | 86.81 ± 19.2 | 85.22 ± 18.7 | 85.41 ± 19.8 | 0.722 |
Ischemic heart disease (%) | 358 (88.4) | 89 (89) | 90 (87.4) | 89 (88.1) | 90 (89.1) | 0.978 |
Diabetes mellitus (%) | 170 (42) | 42 (42) | 38 (36.9) | 50 (49.5) | 40 (39.6) | 0.299 |
Hypertension (%) | 194 (47.9) | 47 (47) | 51 (49.5) | 50 (49.5) | 46 (45.5) | 0.926 |
Stroke (%) | 18 (4.4) | 4 (4) | 5 (4.9) | 4 (4) | 5 (5) | 0.977 |
Kidney diseases (%) | 179 (44.2) | 44 (44) | 47 (45.6) | 46 (45.5) | 42 (41.6) | 0.932 |
COPD (%) | 142 (35.1) | 41 (41)d | 35 (34) | 45 (44.6) | 21 (20.8) | 0.002 |
Smoking status (%) | 152 (37.5) | 38 (38) | 36 (35) | 37 (36.6) | 41 (40.6) | 0.864 |
Systolic blood pressure (mmHg) | 121.01 ± 26.9 | 122.79 ± 26.9 | 121.01 ± 23.8 | 119.58 ± 24.2 | 120.68 ± 25.5 | 0.839 |
Diastolic blood pressure (mmHg) | 75.67 ± 15.68 | 76.26 ± 16.6 | 75.54 ± 15.2 | 75.76 ± 14.1 | 75.14 ± 16.8 | 0.967 |
Left ventricular ejection fraction (%) | Â | Â | Â | Â | Â | Â |
 < 30 | 299 (73.8) | 73 (73) | 70 (68) | 78 (77.2) | 78 (77.2) | 0.391 |
 30–40 | 61 (15.1) | 18 (18) | 17 (16.5) | 12 (11.9) | 14 (13.9) |  |
 40–50 | 27 (6.7) | 3 (3) | 9 (8.7) | 9 (8.9) | 6 (5.9) |  |
 > 50 | 18 (4.4) | 6 (6) | 7 (6.8) | 2 (2) | 3 (3) |  |
Hemoglobin (g/dl) | 13.59 ± 3 | 14.27 ± 3b | 13.79 ± 2.3 | 13.08 ± 3.5 | 13.23 ± 3 | 0.021 |
WBC (106/l) | 5.4 ± 3.1 | 8.1 ± 3.7a,b,c | 5.8 ± 2.9 | 4.1 ± 2.1 | 3.4 ± 0.6 | < 0.001 |
Neutrophils (%) | 68 ± 12.3 | 60.8 ± 14a,b,c | 68.4 ± 10.6 | 66.8 ± 11.1 | 76 ± 8.1 | < 0.001 |
Lymphocytes (%) | 22 ± 9.5 | 28.1 ± 10.3a,b,c | 23 ± 9.2 | 22 ± 6.9 | 15.1 ± 6.3 | < 0.001 |
Platelets (109/l) | 190.45 ± 68.9 | 160.23 ± 65.6b,c | 175.28 ± 49.4 | 198.32 ± 59.9 | 227.97 ± 78.8 | < 0.001 |
Sodium (mEq/l) | 136.07 ± 4.8 | 137.42 ± 7b,c | 136.5 ± 2.9 | 135.6 ± 3.8 | 134.76 ± 4.4 | 0.001 |
Potassium (mEq/l) | 3.97 ± 0.5 | 3.98 ± 0.5 | 3.93 ± 0.5 | 3.97 ± 0.5 | 4.01 ± 0.5 | 0.762 |
Blood urea nitrogen (mg/dl) | 83.36 ± 52.2 | 82.61 ± 60.9 | 84.22 ± 45.8 | 80.41 ± 48.8 | 86.2 ± 52.9 | 0.881 |
Creatinine (mg/dl) | 1.56 ± 1.2 | 1.42 ± 0.7 | 1.50 ± 0.5 | 1.47 ± 0.7 | 1.84 ± 2.2 | 0.077 |
Drug history | Â | Â | Â | Â | Â | Â |
 Pre-admission |  |  |  |  |  |  |
  Beta blocker (%) | 158 (39) | 44 (44) | 40 (38.8) | 34 (33.7) | 40 (39.6) | 0.517 |
  ACEIs/ARBs (%) | 200 (49.4) | 47 (47) | 46 (44.7) | 54 (53.5) | 53 (52.5) | 0.531 |
  Diuretics (%) | 271 (66.9) | 62 (62) | 72 (69.9) | 72 (71.3) | 65 (64.4) | 0.444 |
  Statins (%) | 205 (50.6) | 53 (53) | 48 (46.6) | 55 (54.5) | 49 (48.5) | 0.645 |
  Oral anti-coagulants (%) | 108 (26.7) | 23 (23) | 31 (30.1) | 30 (29.7) | 24 (23.8) | 0.528 |
 Discharge |  |  |  |  |  |  |
  Beta blocker (%) | 273 (67.4) | 67 (67) | 72 (69.9) | 68 (67.3) | 66 (65.3) | 0.920 |
  ACEIs/ARBs (%) | 192 (47.4) | 49 (49) | 50 (48.5) | 49 (48.5) | 44 (43.6) | 0.849 |
  Diuretics (%) | 326 (80.5) | 82 (82) | 87 (84.5) | 78 (77.2) | 79 (78.2) | 0.532 |
  Oral anti-coagulants (%) | 113 (27.9) | 20 (20) | 29 (28.2) | 37 (36.6) | 27 (26.7) | 0.072 |